Alzheimer’s/PD/DLB biomarker and treatment momentum
Key Questions
What new blood tests are advancing for Alzheimer's detection in primary care?
Blood tests like p-tau217/GFAP, GPND-Ai, and PrecivityAD are moving into primary care settings, with ALZpath-Abbott partnerships and Sysmex automated platforms supporting broader access. A new finger-prick p-tau217 test enables at-home dementia risk assessment.
How do blood circular RNAs compare to p-tau217 for predicting Alzheimer's?
Elevated circular RNAs in blood predict AD symptoms years before onset and outperform p-tau217 (AUC 0.945 vs 0.877), with a combined model reaching AUC 0.977 according to an NIH-funded study.
What is the p-tau217 clock model and what does it predict?
The p-tau217 clock model forecasts symptom onset 3-4 years in advance, providing an early timeline for intervention based on recent biomarker research.
Which new therapies are highlighted for Alzheimer's and related conditions?
Approved or advancing options include lecanemab, donanemab, suvorexant, Lilly's oral GSM, Buntanetap, Aribio's AR1001 (Phase 3 topline expected 2026), and Zunveyl with positive real-world long-term care data.
What evidence supports the BCG vaccine for Alzheimer's prevention?
Mass General Brigham research shows the BCG vaccine remodels brain immune environments and clears amyloid in healthy older adults, indicating a potential preventive window.
What safety concern is noted with donanemab?
Donanemab (Kisunla) has been linked to seizures in some patients, though real-world cases also demonstrate complete amyloid clearance.
How might creatine supplementation benefit Alzheimer's patients?
A study found that 20g/day of creatine improves cognition in AD over 8 weeks, offering a simple adjunct approach.
What preclinical finding suggests early circuit changes in Alzheimer's?
Prefrontal-striatal circuit overactivity precedes memory deficits, pointing to potential early intervention targets before typical symptoms appear.
Blood tests (p-tau217/GFAP, GPND-Ai, PrecivityAD) advancing to primary care; FDA Breakthrough for urine test; ALZpath-Abbott partnership; Sysmex Europe automated platform. New: blood circRNAs predict AD years before symptoms, outperforming pTau217 (AUC 0.945 vs 0.877), combined AUC 0.977. New: p-tau217 clock model predicts symptom onset 3-4 years ahead. New: finger-prick p-tau217 test for at-home dementia risk assessment. New: preclinical study shows prefrontal-striatal circuit overactivity precedes memory deficits. New therapies: lecanemab/donanemab, suvorexant, Bredesen Protocol, Lilly's oral GSM, Buntanetap, etalanetug. New: Aribio's AR1001 oral DMT completed Phase 3 dosing; topline results Sep-Oct 2026. New: Zunveyl real-world data (BEACON) shows improvements in long-term care. New: Alzheon's ALZ-801 neurovascular evidence. New: GT-02287 (oral GCase activator) FDA clearance for Phase 2 in PD. Safety: donanemab linked to seizures. New: creatine (20g/day) improves cognition in AD over 8 weeks. New: BCG vaccine remodels brain immune environment and clears amyloid in healthy older adults, suggesting preventive window. New: real-world Kisunla (donanemab) patient story shows complete amyloid clearance. New: super-agers study shows twice as many new hippocampal neurons and fewer tau tangles, supporting brain resilience. Expert interview reinforces multi-target approach.